NCT07514429 2026-04-07
RELEVANT-HCC
Asan Medical Center
Phase 2 Not yet recruiting
Clinical Trials
140 trialsNCT07514455 2026-04-07
RECOMEND
Asan Medical Center
Phase 2 Not yet recruiting
NCT04503694 2026-03-27
REGINA
Jules Bordet Institute
Phase 2 Active not recruiting
NCT06902246 2026-03-27
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Recruiting
NCT07495579 2026-03-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT02310477 2026-03-13
REBECCA
Centre Oscar Lambret
Completed
NCT02386397 2026-03-12
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT07137390 2026-03-11
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT04777851 2026-03-09
REPLACE
Translational Research in Oncology
Phase 3 Terminated
NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT06071052 2026-03-05
DREAM
First Affiliated Hospital, Sun Yat-Sen University
Phase 2 Completed
NCT04757363 2026-03-04
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03828799 2026-02-27
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT07223567 2026-02-25
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT07071961 2026-02-17
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT03712943 2026-02-09
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04787341 2026-02-02
PARERE
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT04362839 2026-01-28
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT05672316 2026-01-28
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT04781192 2026-01-23
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT05155189 2026-01-21
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
Zhejiang University
Phase 1 Recruiting
NCT06006923 2026-01-20
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
University of Pittsburgh
Phase 2 Terminated
NCT06087263 2026-01-20
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07343791 2026-01-15
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
Jinling Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT03844620 2026-01-09
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06283134 2026-01-07
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
Phase 1 Not yet recruiting
NCT07213570 2025-12-17
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
National Cancer Institute, Naples
Phase 2 Recruiting
NCT03829462 2025-11-21
NEXT-REGIRI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 3 Active not recruiting
NCT05366816 2025-09-09
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
Phase 2 Recruiting
NCT05194293 2025-09-04
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT06887218 2025-08-27
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT07100392 2025-08-17
LEAF-02
Fudan University
Phase 2 Recruiting
NCT07115550 2025-08-11
A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma
Huai'an First People's Hospital
Phase NA Not yet recruiting
NCT04874207 2025-08-08
RePERSO
Rennes University Hospital
Phase 4 Completed
NCT07078305 2025-07-22
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT03657641 2025-07-04
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
University of Southern California
Phase 1/2 Active not recruiting
NCT02368886 2025-06-18
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT07003022 2025-06-04
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Fudan University
Phase 2 Recruiting
NCT06992648 2025-05-28
REGTAS-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Recruiting
NCT06949982 2025-05-04
x-МАР
Pavlov First Saint Petersburg State Medical University
Phase 2 Recruiting
NCT06946849 2025-04-27
SED-RO-ICC
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06911684 2025-04-23
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
Sun Yat-sen University
Phase 2 Recruiting
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT06930118 2025-04-16
The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
Shanghai Changzheng Hospital
Phase 2 Recruiting
NCT04450836 2025-03-30
SOREGATT
UNICANCER
Phase 2 Terminated
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT03899428 2025-03-24
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Humanity & Health Medical Group Limited
Phase 2 Recruiting
NCT03627728 2025-03-13
a-MANTRA
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT05057052 2025-02-27
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
Fudan University
Phase 2 Recruiting
NCT06456515 2025-02-17
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
The First People's Hospital of Changzhou
Phase NA Recruiting